Videos

Michael B. Atkins, MD, reviews a case involving a female patient who was diagnosed with stage IV BRAF-mutated melanoma, and shares insights on the patient’s prognosis and his approach to diagnosis.

Virginia Kaklamani, MD, presents the case of a 56-year-old woman with HR+/HER2- metastatic breast cancer and visceral metastases.

Paolo Tarantino, MD, discusses what to know about the real-world findings from the RELIEVE study which were presented at the 2023 San Antonio Breast Cancer Symposium.

Following their review of clinical trial data presented at ASH 2023, the Oncology Brothers offer their key takeaways on recent updates in multiple myeloma.

Medical oncologists discuss recent data from KarMMA-3 investigating ide-cel CAR T-cell therapy in patients with triple-class–exposed relapsed/refractory multiple myeloma.

Jens Hillengass, MD, PhD, and the Oncology Brothers discuss a retrospective observational study on real-world bortezomib prescribing patterns and outcomes in newly diagnosed multiple myeloma.

Experts on multiple myeloma review recent data updates from the IsKia study looking at Isa-KRd vs KRd as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma.

Following ASH 2023, Jens Hillengass, MD, PhD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent data from the PERSEUS study investigating Dara-VRd in newly diagnosed multiple myeloma.

Christopher J. Melani, MD, discusses updated data from the phase 1b/2 ViPOR trial of the combination of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, in patients with diffuse large B-cell lymphoma.

Douglas W. Sborov, MD, MS, provides a summary of the key details of the 54-year-old patient's medical history and multiple myeloma diagnosis.

Other considerations between KRAS targeting treatments in patients with KRAS+ mutated NSCLC.

An overview of recognizing and managing common immune-related and systemic adverse events with immune checkpoint inhibitors, chemotherapy and KRAS targeted therapies in NSCLC.

Clinical trial efficacy and safety data between KRAS G12C inhibitors that inform initial treatment selection for patients with NSCLC.

An overview of the role of KRAS G12C inhibitors in the second line and beyond for KRAS G12C mutated NSCLCs after progression on platinum-based chemotherapy.

Cinical trial data and guidelines on optimal first-line regimens for metastatic KRAS mutated lung adenocarcinoma.

Mazyar Shadman, MD, MPH, explains the current standard-of-care treatment for patients with chronic lymphocytic leukemia and details the factors he considers when choosing an appropriate therapy.

Background on KRAS mutations in lung adenocarcinoma, including the prevalence, prognosis, and challenges in treating patients with NSCLC.

Lori Wirth, MD, discusses second-line treatment in relation to the patient case, and concludes the discussion with a look at emerging treatment options and the future of treating advanced RAI-refractory DTC.

An expert on thyroid cancer provides insights on treating patients with advanced RAI-refractory DTC who harbor BRAFV600E mutations.

Dr Garica-Manero provides a brief overview of the current treatment paradigm for lower-risk MDS as well as discussing some unmet needs.

Lori Wirth, MD, discusses molecular testing practices for patients with advanced RAI-refractory differentiated thyroid cancer.

Sandip P. Patel, MD, offers advice to fellow oncologists and highlights unmet needs and future directions in the treatment of patients with non–small cell lung cancer.

A medical oncologist reviews real-world data on older patients with RAI-refractory DTC and provides her thoughts on treating this patient population.

An overview of the standard of care treatment for patients with advanced radioiodine-refractory differentiated thyroid cancer.

A medical oncologist reviews the efficacy and safety outcomes from the ADAURA trial investigating osimertinib in resected EGFR-mutated NSCLC and discusses how biomarkers inform treatment selection.

Lori Wirth, MD, discusses the safety profiles of sorafenib and lenvatinib and provides clinical insights on managing or mitigating adverse effects.

Turning the focus to EGFR inhibitors, Sandip P. Patel, MD, discusses their mechanism action and the improved toxicity profile of next-generation inhibitors.

A medical oncologist provides a comprehensive overview of the current treatment options for patients with advanced RAI-refractory DTC and reviews clinical trial data on sorafenib and lenvatinib.

Expert perspectives on treating patients with non–small cell lung cancer, with a focus on treatment goals and patient factors that inform clinical decision-making and sequencing considerations.

A leading expert on head and neck oncology provides her initial impressions on the case of a 64-year-old woman with differentiated thyroid cancer.